Metabolic completes Phase IIb obesity enrollment

Metabolic Pharmaceuticals (ASX:MBP) completed enrollment of 300 obese patients in a double-blind, placebo-controlled Phase IIb trial of AOD9604. MBP expects data by November. The primary endpoints of ...